
Being Attack-Free With Garadacimab Improves Quality of Life in Patients With Hereditary Angioedema


¹Section of Rheumatology, Department of Medicine, Yale University School of Medicine, Allergy & Immunology, New Haven, CT, USA; ³Klinikum der Johann Wolfgang-Goethe Universität, Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany; ⁴CSL Behring, King of Prussia, PA, USA; ⁵CSL Innovation GmbH, Marburg, Germany; ⁶CSL Behring AG, Bern, Switzerland; ⁷Allergy, Asthma and Immunology, Department of Medicine, Pediatrics and Biomedical Sciences, Pennsylvania State University, Hershey, PA, USA; ⁸Vinmec International Hospital, Times City, Hanoi, Vietnam.



- to QoL¹⁻³
- Phase 3 OLE studies^{1,4}



OLE, open-label extension



*Newly enrolled patients received one SC 400 mg loading dose as their first dose. AE-QoL, Angioedema Quality of Life questionnaire; HAE, hereditary angioedema; HAE-C1INH, HAE due to C1 inhibitor deficiency or dysfunction; OLE, open-label extension; PRO, patient-reported outcome;

QoL, quality of life; TEAE, treatment-emergent adverse event; TSQM, Treatment Satisfaction Questionnaire for Medication; WPAI:GH, Work Productivity and Activity Impairment Questionnaire: General Health.

F. Ida Hsu¹, William R. Lumry², Emel Aygören-Pürsün³, Julia Braverman⁴, John-Philip Lawo⁵, Maressa Pollen⁴, Chiara Nenci⁶, Timothy J. Craig^{7,8}

AE-QoL, Angioedema Quality of Life questionnaire; HRQoL, health-related quality of life; IQR, interquartile range; SD, standard deviation.

References

1. Craig TJ et al. Lancet 2023;401:1079–1090; 2. Bork K et al. Allergy Asthma Clin Immunol 2021;17:40; 3. Maurer M et al. Allergy 2022;77:1961–1990; 4. Reshef A et al. Allergy 2024;doi:10.1111/all.16351 [online ahead of print]; 5. Aygören-Pürsün E et al. Presented at EAACI 2024. Flash talk presentation 1405; 6. Craig TJ et al. Lancet 2022;399:945–955.

AE-QoL, Angioedema Quality of Life guestionnaire; QoL, guality of life.

You must not copy this work without permissic

+612 9394 7600 copyright.com.au

Originally presented at American College of Allergy Asthma & Immunology Annual Scientific Meeting | Boston, MA, USA | October 24–28, 2024

Publication Practice guidelines (www.ismpp.org/gpp-2022).

The study was sponsored by CSL Behring. Medical writing support was provided by Suzanne Berresford,

BPharm, of Helix, OPEN Health Communications, and funded by CSL Behring, in accordance with Good

Disclosures